155 related articles for article (PubMed ID: 18476989)
1. The development of the referral outcome diagram and an analysis of laboratory cancer detection rates in the English NHS cervical screening programme--is there an optimum level of detection of CIN 1 and CIN 2 lesions?
Blanks RG
Cytopathology; 2008 Aug; 19(4):244-53. PubMed ID: 18476989
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
4. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
[TBL] [Abstract][Full Text] [Related]
5. Management and treatment of cervical intraepithelial neoplasia in the Netherlands after referral for colposcopy.
Aitken CA; Siebers AG; Matthijsse SM; Jansen EEL; Bekkers RLM; Becker JH; Ter Harmsel B; Roovers JWR; van Kemenade FJ; de Kok IMCM
Acta Obstet Gynecol Scand; 2019 Jun; 98(6):737-746. PubMed ID: 30687935
[TBL] [Abstract][Full Text] [Related]
6. The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial.
Dalla Palma P; Giorgi Rossi P; Collina G; Buccoliero AM; Ghiringhello B; Lestani M; Onnis G; Aldovini D; Galanti G; Casadei G; Aldi M; Gomes V; Giubilato P; Ronco G;
Am J Clin Pathol; 2008 Jan; 129(1):75-80. PubMed ID: 18089491
[TBL] [Abstract][Full Text] [Related]
7. The use of screening episodes linked to CIN3 and invasive cancer registrations to study outcomes from the NHS Cervical Screening Programme.
Blanks RG; Moss SM; Coleman DA; Addou S; Swerdlow AJ
Cytopathology; 2009 Jun; 20(3):154-60. PubMed ID: 19207309
[TBL] [Abstract][Full Text] [Related]
8. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
[TBL] [Abstract][Full Text] [Related]
9. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
10. Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.
Kyrgiou M; Kalliala IE; Mitra A; Fotopoulou C; Ghaem-Maghami S; Martin-Hirsch PP; Cruickshank M; Arbyn M; Paraskevaidis E
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD009836. PubMed ID: 28125861
[TBL] [Abstract][Full Text] [Related]
11. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
13. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.
Denise Zielinski G; Snijders PJ; Rozendaal L; Voorhorst FJ; Runsink AP; de Schipper FA; Meijer CJ
J Pathol; 2001 Oct; 195(3):300-6. PubMed ID: 11673826
[TBL] [Abstract][Full Text] [Related]
14. Extension of organised cervical cancer screening programmes in Italy and their process indicators.
Ronco G; Giubilato P; Naldoni C; Zorzi M; Anghinoni E; Scalisi A; Dalla Palma P; Zanier L; Federici A; Angeloni C; Prandini S; Maglietta R; Mancini E; Pizzuti R; Iossa A; Segnan N; Zappa M
Epidemiol Prev; 2007; 31(2-3 Suppl 2):33-47. PubMed ID: 17824361
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: systematic reviews and economic evaluation.
Peron M; Llewellyn A; Moe-Byrne T; Walker S; Walton M; Harden M; Palmer S; Simmonds M
Health Technol Assess; 2018 Sep; 22(54):1-260. PubMed ID: 30284968
[TBL] [Abstract][Full Text] [Related]
16. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
[TBL] [Abstract][Full Text] [Related]
17. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
18. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
[No Abstract] [Full Text] [Related]
20. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
Tay TKY; Lim KL; Hilmy MH; Thike AA; Goh ST; Song LH; Hwang JSG; Mantoo S
Malays J Pathol; 2017 Dec; 39(3):257-265. PubMed ID: 29279588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
